Branched-chain amino acid derivatives to treat disease
AssigneeIntrabio Ltd.
InventorGrant Charles Churchill
Life of this patent
Estimating the term…
Abstract
The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, and R3 are as defined as set forth in the specification. The present disclosure also provides compounds having Formula I for use to treat or prevent the progression of a lysosomal storage disorder or a neurodegenerative disease in a subject, provide neuroprotection in a subject having a lysosomal storage disorder, treat or prevent a migraine, and the symptoms associated therewith, in a subject, or improve mobility and/or cognitive function in a subject.
Claims8
A method of treating a disease, disorder, or condition, or a symptom thereof, in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of Formula I:
- or a pharmaceutically acceptable salt or solvate thereof, wherein:
- R1 is selected from the group consisting of:
- R2 is selected from the group consisting of C2-C6 alkyl and C3-C6 cycloalkyl;
- and
- R3 is selected from the group consisting of hydrogen, C1-C6 alkyl, and C3-C6 cycloalkyl,
- or a pharmaceutically acceptable salt or solvate thereof, wherein the disease, disorder, or condition is a lysosomal storage disorder, a neurodegenerative disease, a traumatic brain injury, or a migraine.
Dependencies are inferred from the claim text.